A global leader in interventional pulmonology, planning tools, and treatments for obstructive lung disease. Based in Redwood City, California (USA), and Neuchâtel (CH), Pulmonx is the maker of the Zephyr Endobronchial Valve. The Zephyr® Valve was granted breakthrough status and approved by the FDA in June 2018, because according to the FDA it “represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. The device offers a significant, clinically meaningful advantage over the current standard of care and therefore, its availability is also in the best interest of patients.”20 (References: https://pulmonx.com/references/)